- Covance experts to present best practices for improving drug
safety and reducing R&D time, cost - PRINCETON, N.J., June 16
/PRNewswire-FirstCall/ -- Covance Inc. is pleased to announce the
complete list of experts scheduled to present at the Drug
Information Association's (DIA) 45th Annual Meeting from June
21-25, 2009 in San Diego, Calif. The DIA Annual Meeting is the
biopharmaceutical industry's largest, longest running, global,
multidisciplinary event. This year's program offers learning
opportunities for everyone and features the biggest names from
industry, regulatory, and academia. Building on the conference
theme, "Better Medicines: Improving Safety with Every Step,"
Covance experts will present best practices for improving safety
while reducing the time and cost of drug development, including:
June 22, 2009: -- "Innovation at a CRO: A Strategic Management
Platform to Enhance Overall Value of a Client's Portfolio" 10:30
a.m. | Speaker: Krish Ghosh, PhD, vice president, resource
management -- "Issues and Challenges Associated with the PSUR
Process" 1:30 p.m. | Session Chair: Robert Bader, PharmD, senior
director, product safety, periapproval services -- "Improving
Safety with Expanded Training Options for Physicians in Early
Phases of Clinical Research" 1:30 p.m. | Speaker: Russ Dixon, MD,
medical director, early clinical development -- "EDC Front to Back:
Streamline Processes End-to-End for True Operational Benefit" 3:30
p.m. | Speaker: Ross Rothmeier, senior director, EDC portfolio,
clinical development services June 23, 2009: -- "Corrective Action
and Preventive Action Program for Clinical Trial Programs" 8:00
a.m. | Session Chair: Bruce Wagman, MBA, RN, RAC, vice president,
regulatory affairs and quality assurance, clinical development
services -- "Routine Monitoring Visits: Pragmatic Approaches to
Reduce Prep Time by More Than 50%" 9:30 a.m. | Poster Presentation:
Ann Flandermeyer, BSN, PhD, MSN, RN, project management and
clinical operations -- "Early Exposure to the Science of Safety
Through Clinical Research in a CRO Setting for Future Medical
Professionals" 9:30 a.m. | Poster Presentation: Jackie
Miller-Giles, MT (ASCP), MS, global clinical pharmacology --
"Nonclinical Support for First-in-Human Clinical Trials" 2:00 p.m.
| Speaker: Paul Baldrick, PhD, head of department, pharmaceutical
regulatory affairs -- "Defining Quality in Clinical Trials (2nd
Annual Update)" 2:00 p.m. | Session Chair: John Poland, PhD, senior
director, regulatory policy, UK, clinical development services --
"Changes in the WHO Review of Psychoactive Substances for
International Control" 4:00 p.m. | Session Chair: Edgar Adams, ScD,
MS, executive director, epidemiology, periapproval services --
"Site Preferences for EDC - A Comparison of European and North
American Perspectives" 4:00 p.m. | Session Chair: Eunice
Franklin-Becker, MPH, senior project manager, registries and
observational studies, periapproval services -- "First-In-Human
Trial Designs: How Much is Too Much?" 4:00 p.m. | Session Chair:
Mary Westrick, PhD, global vice president and general manager,
clinical pharmacology June 24, 2009: -- "Six Sigma: How to Leverage
'A Great Idea' in the Complex Reality of Clinical Trials" 8:30 a.m.
| Session Chair: Tim G. Strauss, MA, executive director, business
process improvement, clinical development services -- "Outsourced
Data Management: How to Align Performance Expectations" 10:30 a.m.
| Session Chair: Mark Anderson, senior director, data management,
clinical development services -- "Site Activation: How to Get
Beyond the Classic Pitfalls" 1:30 p.m. | Speaker: Heather Almonte,
MBA, RAC, senior manager, site activation, clinical development
services -- "An Overview of Challenges and Strategies to Make
Remote Investigator Training a Reality" 3:30 p.m. | Speaker:
Christina Werremeyer, project manager, periapproval services --
"Latin America: Leveraging Regional Strengths While Proactively
Ensuring Quality" 3:30 p.m. | Session Chair: Katie Margules,
PharmD, MSc, senior director, clinical development services, Latin
America June 25, 2009: -- "Proactive Management of Project
Financials: Understand Scope of Work, Cost to Complete, and Scope
Change" 8:30 a.m. | Session Chair: Ann Flandermeyer, BSN, PhD, MSN,
RN, senior director, project management and clinical operations,
clinical development services -- "Preserving Relationships in the
Face of Divergent Project Expansions" 8:30 a.m. | Speaker: Mike
Hill, project manager, periapproval services -- "Preclinical Safety
Evaluation of Novel Adjuvants and Vaccines" 10:30 a.m. | Session
Chair: Peter Thomas, PhD, senior program manager, strategic
partnering & integrated drug development About Covance Covance,
with headquarters in Princeton, New Jersey, is one of the world's
largest and most comprehensive drug development services companies
with annual revenues greater than $1.5 billion, global operations
in more than 25 countries, and more than 9,600 employees worldwide.
Information on Covance's products and services, recent press
releases, and SEC filings can be obtained through its website at
http://www.covance.com/. About the Drug Information Association
(DIA) DIA serves more than 30,000 biopharmaceutical professionals
from industry, academia, and regulatory agencies worldwide. Through
its domestic and international meetings, training courses,
workshops and webinars, DIA provides a neutral global forum for the
exchange of information critical to the advancement of the drug
discovery and lifecycle management processes. Headquartered in
Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo,
Japan, Mumbai, India, and Beijing, China, the Association is led by
its volunteer-based Board of Directors and executive management
team. For more information, visit http://www.diahome.org/ or call
215.442.6100. Statements contained in this press release, which are
not historical facts, are forward-looking statements pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. All such forward-looking statements including
the statements contained herein regarding anticipated trends in the
Company's business are based largely on management's expectations
and are subject to and qualified by risks and uncertainties that
could cause actual results to differ materially from those
expressed or implied by such statements. These risks and
uncertainties include, without limitation, competitive factors,
outsourcing trends in the pharmaceutical industry, levels of
industry research and development spending, the Company's ability
to continue to attract and retain qualified personnel, the fixed
price nature of contracts or the loss of large contracts, and other
factors described in the Company's filings with the Securities and
Exchange Commission. DATASOURCE: Covance Inc. CONTACT: Media
Relations, +1-609-419-2466, or Investor Relations, +1-609-452-4807
Web Site: http://www.covance.com/
Copyright